Exact Sciences Cor (EXAS) Stock Price, Quote & News

Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic,...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 608 284 5700

Website: www.exactsciences.com

Address:

5505 Endeavor Lane, Madison, United States

SuperGreenToday Feb. 22 at 4:36 PM

$EXAS Share Price: $103.44 Contract Selected: Jul 17, 2026 $105 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 64% ROI Time to Expiration: 144 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

UgoGreg Feb. 20 at 10:31 PM

$EXAS https://youtu.be/QTb6KRPLkts

0 · Reply

AStrokeOfLuck Feb. 20 at 9:19 PM

$EXAS

0 · Reply

meatpuppets Feb. 20 at 3:15 PM

$GRAL how did algos know to cut this in 1/2 post close??? $EXAS sold for 20BB. ridiculous selloff.

0 · Reply

outlawinvestor1 Feb. 20 at 2:35 PM

$GRAL i'm not an investor, but i think $GRAL $EXAS $GH tests are all going to be part of the future of cancer screening soc. i will be a user and may become an investor.

1 · Reply

Mergerbrief Feb. 20 at 1:10 PM

$EXAS / $ABT – Shareholder Vote EXAS

0 · Reply

Napoliblue Feb. 20 at 4:00 AM

$CDIO yes they made a comparison Abbott Laboratories $ABT bought Cologuard for $21 Billion from $EXAS Cologuard started around August 2014 when it received FDA approval and began being offered to patients through healthcare providers. So it took nine years to get bought out. CDIO has been around only 3 years and their test kits for heart disease is expanding in Africa, India, Japan and Australia. BOTTOM LINE FUTURE LOOKS BRIGHT Specific segments (like cardiovascular drugs) are forecast to reach hundreds of billions by the early 2030s. The company has growing pains but once they turn the corner it’s gonna be worth the investment. Heart Disease is the number killer Globally. I’m holding long term with size .

0 · Reply

meatpuppets Feb. 19 at 10:47 PM

$GRAL $EXAS exact getting bought for 20 BB. detection works. Grail gonna tweek and tune. Gift of the magi. trading way less than what someone gonna swllow it for

1 · Reply

BillionerOfKing Feb. 19 at 10:20 PM

$EXAS Current Stock Price: $103.28 Contracts to trade: $105.0 EXAS Feb 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 52% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ZacksResearch Feb. 19 at 2:13 PM

$EXAS just delivered the kind of quarter bulls have been waiting for. 🚀 Q4 revenue beat expectations, driven by growth in Screening and Precision Oncology, margins expanded, shares ticked up, and Abbott merger plans moved forward — that’s multiple catalysts lining up at once. Momentum building here. Get the full breakdown 👉 https://www.zacks.com/stock/news/2871858/exact-sciences-q4-earnings-match-estimates-revenues-beat-stock-up?cid=sm-stocktwits-2-2871858-teaser-34195&ADID=SYND_STOCKTWITS_TWEET_2_2871858_TEASER_34195

0 · Reply

Exact Sciences Stockholders Approve Acquisition by Abbott

ABT

Feb 15, 2026, 6:08 PM EST - 10 days ago

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

ABT ALKT CDNA CWAN DKNG DT ESTA

Feb 13, 2026, 4:05 PM EST - 12 days ago

Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 12:38 PM EST - 13 days ago

Alger Mid Cap 40 ETF Q4 2025 Portfolio Update

HOOD MDB MU NBIS RBLX

Feb 12, 2026, 1:20 AM EST - 14 days ago

Baron Opportunity Fund Q4 2025 Portfolio Activity

AXON DUOL GTLB HTFL ONON TTD

Feb 6, 2026, 4:03 PM EST - 19 days ago

Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences' '746 Patent

Feb 3, 2026, 2:32 PM EST - 22 days ago

Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

Feb 3, 2026, 9:03 AM EST - 22 days ago

Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

Jan 29, 2026, 1:22 PM EST - 27 days ago

Alger Small Cap Focus Fund Q4 2025 Portfolio Update

GH NBIS NTRA QURE STVN

Jan 26, 2026, 3:54 AM EST - 4 weeks ago

Alger Small Cap Growth Fund Q4 2025 Portfolio Update

GH NBIS NTRA RZLT WIX

Jan 22, 2026, 5:15 AM EST - 4 weeks ago

Alger Mid Cap Focus Fund Q4 2025 Portfolio Update

GH HOOD NBIS NTRA RBLX

Jan 2, 2026, 8:58 AM EST - 7 weeks ago

Top 2 Health Care Stocks That May Crash In Q1

TEVA

Dec 30, 2025, 9:31 AM EST - 2 months ago

Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims

Dec 11, 2025, 5:30 PM EST - 2 months ago

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

Dec 2, 2025, 9:01 AM EST - 3 months ago

Top 2 Health Care Stocks You May Want To Dump This Month

HAE

Nov 24, 2025, 4:35 PM EST - 3 months ago

Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

Nov 21, 2025, 8:30 PM EST - 3 months ago

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

ABT

Nov 20, 2025, 6:45 PM EST - 3 months ago

Why the Stock Price of This Cancer Screening Company Soared 17% Thursday

Nov 20, 2025, 5:03 PM EST - 3 months ago

Exact Sciences Corporation (EXAS) M&A Call Transcript

Nov 20, 2025, 3:13 PM EST - 3 months ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS)

Nov 20, 2025, 1:29 PM EST - 3 months ago

Is it too late to buy Exact Sciences stock after Abbott's $21B deal?

Nov 20, 2025, 1:26 PM EST - 3 months ago

Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More

BBWI NVDA WMT

Nov 20, 2025, 9:37 AM EST - 3 months ago

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

ABT

Nov 20, 2025, 8:43 AM EST - 3 months ago

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

ABT

Nov 20, 2025, 7:46 AM EST - 3 months ago

Abbott to Acquire Exact Sciences for $21 Billion

ABT

Nov 20, 2025, 7:46 AM EST - 3 months ago

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.

ABT

Nov 20, 2025, 7:36 AM EST - 3 months ago

Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences

ABT

Nov 20, 2025, 7:30 AM EST - 3 months ago

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

ABT

Nov 19, 2025, 4:27 PM EST - 3 months ago

Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories

ABT

Nov 19, 2025, 1:50 PM EST - 3 months ago

Abbott is weighing takeover of Exact Sciences, Bloomberg News reports

ABT

Nov 18, 2025, 9:28 AM EST - 3 months ago

Exact Sciences Corporation (EXAS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 15, 2025, 7:41 AM EST - 3 months ago

Exact Sciences Corporation (EXAS) Presents at 7th Annual Healthcare Symposium Transcript

Nov 10, 2025, 7:00 AM EST - 3 months ago

Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome's Blood-Based Colorectal Cancer Screening Tests

Nov 7, 2025, 8:00 AM EST - 3 months ago

Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test

Nov 4, 2025, 9:25 AM EST - 4 months ago

These Analysts Raise Their Forecasts On Exact Sciences Following Better-Than-Expected Q3 Results

Nov 4, 2025, 7:00 AM EST - 4 months ago

Exact Sciences to Participate in November Investor Conference

Nov 4, 2025, 2:16 AM EST - 4 months ago

Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:05 PM EST - 4 months ago

Exact Sciences Announces Third Quarter 2025 Results

Oct 27, 2025, 7:00 AM EDT - 4 months ago

Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps

Oct 8, 2025, 7:00 AM EDT - 5 months ago

Exact Sciences Schedules Third Quarter 2025 Earnings Call

Oct 7, 2025, 6:59 AM EDT - 5 months ago

New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies

Sep 25, 2025, 5:07 AM EDT - 5 months ago

Exact Sciences' Clear Expansion Path: Why Choose To Buy

Sep 22, 2025, 7:00 AM EDT - 5 months ago

Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test

Sep 17, 2025, 8:30 AM EDT - 5 months ago

Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive Care

Sep 15, 2025, 3:30 PM EDT - 5 months ago

Exact Sciences CEO on Launch of Multi-Cancer Blood Test

Sep 10, 2025, 6:30 AM EDT - 6 months ago

Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

SuperGreenToday Feb. 22 at 4:36 PM

0 · Reply

UgoGreg Feb. 20 at 10:31 PM

$EXAS https://youtu.be/QTb6KRPLkts

0 · Reply

AStrokeOfLuck Feb. 20 at 9:19 PM

$EXAS

0 · Reply

meatpuppets Feb. 20 at 3:15 PM

$GRAL how did algos know to cut this in 1/2 post close??? $EXAS sold for 20BB. ridiculous selloff.

0 · Reply

outlawinvestor1 Feb. 20 at 2:35 PM

$GRAL i'm not an investor, but i think $GRAL $EXAS $GH tests are all going to be part of the future of cancer screening soc. i will be a user and may become an investor.

1 · Reply

Mergerbrief Feb. 20 at 1:10 PM

$EXAS / $ABT – Shareholder Vote EXAS

0 · Reply

Napoliblue Feb. 20 at 4:00 AM

0 · Reply

meatpuppets Feb. 19 at 10:47 PM

$GRAL $EXAS exact getting bought for 20 BB. detection works. Grail gonna tweek and tune. Gift of the magi. trading way less than what someone gonna swllow it for

1 · Reply

BillionerOfKing Feb. 19 at 10:20 PM

0 · Reply

ZacksResearch Feb. 19 at 2:13 PM

0 · Reply

ZacksResearch Feb. 19 at 1:13 PM

$EXAS Q4: Mixed Signals with Revenue Beat But Rising Losses 📉 Exact Sciences matched EPS estimates with a net loss of 21 cents, while fourth-quarter consolidated revenue surged 23.1%, beating the Zacks Consensus Estimate by 2.1%. Yet, escalating expenses and an adjusted operating loss of $82.2 million raise concerns. See the full analysis here 👉 https://www.zacks.com/stock/news/2871858/exact-sciences-q4-earnings-match-estimates-revenues-beat-stock-up?cid=sm-stocktwits-2-2871858-body-34159&ADID=SYND_STOCKTWITS_TWEET_2_2871858_BODY_34159

0 · Reply

THECORLEONEFAMILY Feb. 17 at 5:07 PM

$ALTS $EXAS $STX $ALT $XRP.X

0 · Reply

d_risk Feb. 15 at 10:09 PM

$EXAS - Exact Sciences Corporation - 10K - Updated Risk Factors EXAS’s 2026 10-K ramps up deal and regulatory risk: a new Merger risk bucket (approval, litigation, costs, breakup overhang) dominates, while expanded sections flag heavier leverage, complex reimbursement and billing scrutiny, LDT/FDA uncertainty, AI and pandemic exposure, and deeper dependence on key cancer tests, vendors, IP deals, and acquisitions. #Biotechnology #MergerRisk #RegulatoryCompliance #HealthcareReimbursement #CancerDiagnostics 🟢 Added 🟠 Removed https://d-risk.ai/EXAS/10-K/2026-02-13

0 · Reply

Arifshanta Feb. 14 at 11:56 PM

$EXAS

0 · Reply

Woodman7 Feb. 14 at 4:18 PM

$ABT - check $EXAS recent earnings release. $ABT caught a diamond in the rough for cheap. 23% growth in 4Q25! That oughta spark a little bit of growth in 2026 and beyond

1 · Reply

DonCorleone77 Feb. 14 at 3:41 PM

$EXAS Exact Sciences reports Q4 EPS (45c) vs (27c) last year Reports Q4 revenue $878M, consensus $860.76M. "In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests," said Kevin Conroy, Chairman and CEO of Exact Sciences. "These defining milestones show what the Exact Sciences team can achieve through a relentless focus on our mission and a dedication to improving the lives of patients. As we look to the future, momentum continues to build. Our core products are driving strong growth, our portfolio is expanding, and we are uniquely positioned to drive lasting change in the way cancer is found and treated globally."

0 · Reply

briefingcom Feb. 9 at 1:36 PM

$EXAS: Exact Sciences: Geneoscopy wins second patent trial and appeal board decision, invalidating all challenged claims of Exact Sciences’ ’746 patent https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260209051932EXAS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

aristocks Feb. 7 at 1:10 AM

$EXAS $GH $PSIX $SYM what a monster $PSIX

0 · Reply

Stockjoe19 Feb. 5 at 12:53 PM

$SLV $AG $EXAS $CDE Silver needs to see a move up rather soon otherwise another flush lower coming. The chart can’t take TOO MUCH more downside here before it will fold down again. Will be analyzing this AM….hope we can hold these levels as an unwind is not what I’d like to do here.

0 · Reply

NeoNebula Feb. 4 at 11:05 AM

$EXAS faces increasing competition in liquid biopsies; Colonoscopy remains the gold standard, limiting test adoption rates.

1 · Reply

SuperGreenToday Feb. 3 at 11:58 PM

$EXAS Share Price: $102.52 Contract Selected: May 15, 2026 $105 Calls Buy Zone: $0.34 – $0.43 Target Zone: $0.60 – $0.74 Potential Upside: 65% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Kleeno Feb. 3 at 2:29 PM

$EXAS saw my first CancerGuard commercial during FBI Llast night on CBS. Argh!!!!!

0 · Reply

Market Cap	19.75B
Revenue (ttm)	3.25B
Net Income (ttm)	-207.95M
EPS (ttm)	N/A
PE Ratio	2,584.75
Forward PE	71.30
Profit Margin	-6.40%
Debt to Equity Ratio	0.00

Volume	2,243,700
Avg Vol	2,496,198
Day's Range	N/A - N/A
Shares Out	190.89M
Stochastic %K	25%
Beta	1.42
Analysts	Sell
Price Target	$101.44